fbpx Skip to main content

Incident conditions that may be attributable to COVID-19 are common among adult COVID-19 survivors, according to research published in the May 24 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Lara Bull-Otterson, Ph.D., from the CDC COVID-19 Emergency Response Team, and colleagues used electronic health record data during March 2020 to November 2021 to examine the incidence of 26 conditions often attributable to post-COVID among patients with a previous COVID-19 diagnosis (case patients) compared with matched patients without evidence of COVID-19 (controls). Analyses were stratified by age groups (18 to 64 and ≥65 years). Follow-up was for 30 to 365 days after the index encounter.

The researchers found that 38 percent of case patients and 16 percent of controls experienced an incident condition. Multiple systems were affected by conditions, which included cardiovascular, pulmonary, hematologic, renal, endocrine, gastrointestinal, musculoskeletal, neurologic, and psychiatric signs and symptoms.

The highest risk ratios were seen for acute pulmonary embolism (risk ratios, 2.1 and 2.2 for those aged 18 to 64 and ≥65 years, respectively) and respiratory signs and symptoms (risk ratio, 2.1 for both age groups). For those aged 18 to 64 years, 35.4 and 14.6 percent of case patients and controls experienced an incident condition, respectively; among those aged ≥65 years, the corresponding proportions were 45.4 and 18.5 percent.

In other words, one in five and one in four COVID-19 survivors aged 18 to 64 and ≥65 years, respectively, experienced an incident condition.

“These findings can increase awareness for post-COVID conditions and improve post-acute care and management of patients after illness,” the authors write.

You May Also Like::  ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer

Abstract/Full Text

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More